Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jul 2;12(7):1940-2.
doi: 10.1080/21645515.2016.1143159.

Clarification on the impact of cervarix vaccination on human papillomavirus infection and cervical cancer in the United Kingdom

Darron Brown  1 , Amit Sharad Kulkarni  2 , Matt Pillsbury  2 , Alain Luxembourg  2 , Alfred Saah  2
Affiliations
Comment

Clarification on the impact of cervarix vaccination on human papillomavirus infection and cervical cancer in the United Kingdom

Darron Brown et al. Hum Vaccin Immunother. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Estimated Human Papillomavirus (HPV) (types 16/18/31/33/45/52/58)-related incidences of cervical cancer (A), cervical intraepithelial neoplasia (CIN)1 (B), CIN2/3 (C) among females over 100 y.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Van Effelterre TP, Hogea C, Taylor SM. Projected impact of Cervarix(R) vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom. Hum Vaccin Immunother 2016; 12:8–19; PMID:25984886; http://dx.doi.org/10.1080/21645515.2015.1054584 - PMC - PubMed
    1. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al.. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4 - DOI - PubMed
    1. Kjaer SK, Nygard M, Dillner J, Munk C, Marshall B, Hansen B, Sigurdardottir L, Hortlund M, Tryggvadottir L, Saah A. Long-Term Effectiveness and Safety af Gardasil™ in the Nordic Countries. European Res Organization Genital Infect Neoplasia February 4–7. 2015. Oc 6–1 Available at http://www.eurogin.com/2015/images/pdf/eurogin-2015_abstracts_part_2.pdf (accessed 21December2015)
    1. Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014; 10:2147-62; PMID:25424918; http://dx.doi.org/10.4161/hv.29532 - DOI - PMC - PubMed
    1. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781-89; PMID:22920953; http://dx.doi.org/10.1016/S1473-3099(12)70187-1 - DOI - PubMed

Publication types

Substances